BiotechTube

Golimumab + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spondylitis, Ankylosing

Conditions

Spondylitis, Ankylosing

Trial Timeline

Feb 13, 2012 → Jan 15, 2015

NCT ID
NCT01453725

About Golimumab + Placebo

Golimumab + Placebo is a phase 3 stage product being developed by Johnson & Johnson for Spondylitis, Ankylosing. The current trial status is completed. This product is registered under clinical trial identifier NCT01453725. Target conditions include Spondylitis, Ankylosing.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01453725Phase 3Completed

Competing Products

20 competing products in Spondylitis, Ankylosing

See all competitors
ProductCompanyStageHype Score
InfliximabCelltrionPhase 1
33
InfliximabCelltrionPhase 1
33
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
52
adalimumabEisaiPhase 3
77
Ixekizumab + Placebo + AdalimumabEli LillyPhase 3
77
Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved
85
GolimumabJohnson & JohnsonApproved
85
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 2/3
65
placebo for risankizumab + risankizumabAbbViePhase 2
52
Upadacitinib + PlaceboAbbViePhase 2
52
AdalimumabAbbViePre-clinical
23
infliximab + PlaceboMerckPhase 3
77
InfliximabMerckApproved
85
Infliximab + Placebo + NaproxenMerckPhase 3
77
InfliximabMerckPre-clinical
23
GolimumabMerckApproved
85
RemicadeMerckApproved
85
RemicadeMerckApproved
85
InfliximabMerckApproved
85
InfliximabMerckApproved
85

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved
85
Nicotine Gum + Nicotine PatchApproved
85
galantamineApproved
85
IbrutinibApproved
85
Paliperidone ERApproved
85